Emily Field
Stock Analyst at Barclays
(0.96)
# 3,856
Out of 5,182 analysts
15
Total ratings
25%
Success rate
-3.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Field
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Initiates: Underweight | $25 | $27.34 | -8.56% | 1 | Feb 20, 2026 | |
| MRK Merck & Co. | Initiates: Overweight | $140 | $120.15 | +16.52% | 1 | Feb 20, 2026 | |
| GILD Gilead Sciences | Initiates: Equal-Weight | $155 | $139.03 | +11.49% | 1 | Feb 20, 2026 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $1,350 | $929.55 | +45.23% | 1 | Feb 20, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $75 | $58.06 | +29.18% | 1 | Feb 20, 2026 | |
| BIIB Biogen | Initiates: Equal-Weight | $185 | $176.37 | +4.90% | 1 | Feb 20, 2026 | |
| AMGN Amgen | Initiates: Equal-Weight | $350 | $349.82 | +0.05% | 1 | Feb 20, 2026 | |
| ABBV AbbVie | Initiates: Overweight | $275 | $206.47 | +33.19% | 1 | Feb 20, 2026 | |
| NVO Novo Nordisk | Downgrades: Equal-Weight | n/a | $37.98 | - | 1 | Jul 30, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | n/a | $28.56 | - | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | n/a | $58.94 | - | 4 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $809.27 | - | 1 | Oct 19, 2021 |
Pfizer
Feb 20, 2026
Initiates: Underweight
Price Target: $25
Current: $27.34
Upside: -8.56%
Merck & Co.
Feb 20, 2026
Initiates: Overweight
Price Target: $140
Current: $120.15
Upside: +16.52%
Gilead Sciences
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $155
Current: $139.03
Upside: +11.49%
Eli Lilly and Company
Feb 20, 2026
Initiates: Overweight
Price Target: $1,350
Current: $929.55
Upside: +45.23%
Bristol-Myers Squibb Company
Feb 20, 2026
Initiates: Overweight
Price Target: $75
Current: $58.06
Upside: +29.18%
Biogen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $185
Current: $176.37
Upside: +4.90%
Amgen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $350
Current: $349.82
Upside: +0.05%
AbbVie
Feb 20, 2026
Initiates: Overweight
Price Target: $275
Current: $206.47
Upside: +33.19%
Novo Nordisk
Jul 30, 2025
Downgrades: Equal-Weight
Price Target: n/a
Current: $37.98
Upside: -
Galapagos NV
Jan 23, 2025
Downgrades: Underweight
Price Target: n/a
Current: $28.56
Upside: -
Nov 5, 2021
Upgrades: Equal-Weight
Price Target: n/a
Current: $58.94
Upside: -
Oct 19, 2021
Upgrades: Overweight
Price Target: n/a
Current: $809.27
Upside: -